AlphaStar Capital Management LLC bought a new position in shares of PRA Health Sciences Inc (NASDAQ:PRAH) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 3,285 shares of the medical research company’s stock, valued at approximately $299,000.
Other institutional investors and hedge funds have also made changes to their positions in the company. IFP Advisors Inc increased its holdings in shares of PRA Health Sciences by 19,083.3% during the fourth quarter. IFP Advisors Inc now owns 1,151 shares of the medical research company’s stock worth $105,000 after purchasing an additional 1,145 shares during the period. Carroll Financial Associates Inc. increased its holdings in shares of PRA Health Sciences by 127.4% during the third quarter. Carroll Financial Associates Inc. now owns 1,410 shares of the medical research company’s stock worth $112,000 after purchasing an additional 790 shares during the period. Intrust Bank NA bought a new position in shares of PRA Health Sciences during the fourth quarter worth approximately $204,000. Parametrica Management Ltd bought a new position in shares of PRA Health Sciences during the fourth quarter worth approximately $232,000. Finally, Comerica Bank bought a new position in shares of PRA Health Sciences during the third quarter worth approximately $214,000. 97.15% of the stock is currently owned by institutional investors.
In other PRA Health Sciences news, VP Linda Baddour sold 67,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $90.27, for a total value of $6,048,090.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider David W. Dockhorn sold 72,850 shares of the firm’s stock in a transaction that occurred on Thursday, December 28th. The shares were sold at an average price of $90.83, for a total transaction of $6,616,965.50. The disclosure for this sale can be found here. Insiders sold 212,700 shares of company stock worth $19,282,021 in the last 90 days. Company insiders own 2.10% of the company’s stock.
PRA Health Sciences Inc (NASDAQ:PRAH) opened at $82.99 on Friday. The stock has a market cap of $5,260.00, a P/E ratio of 46.62, a P/E/G ratio of 1.19 and a beta of 0.31. The company has a debt-to-equity ratio of 1.38, a current ratio of 1.01 and a quick ratio of 1.01. PRA Health Sciences Inc has a one year low of $57.72 and a one year high of $95.90.
PRA Health Sciences (NASDAQ:PRAH) last announced its quarterly earnings data on Wednesday, February 21st. The medical research company reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.02. PRA Health Sciences had a net margin of 5.64% and a return on equity of 21.66%. The business had revenue of $568.80 million for the quarter, compared to analysts’ expectations of $543.78 million. During the same period last year, the firm posted $0.71 earnings per share. The firm’s quarterly revenue was up 37.5% compared to the same quarter last year. equities analysts anticipate that PRA Health Sciences Inc will post 3.2 EPS for the current fiscal year.
Several brokerages have recently commented on PRAH. Credit Suisse Group raised their target price on shares of PRA Health Sciences from $101.00 to $104.00 and gave the stock an “outperform” rating in a report on Thursday. BidaskClub cut shares of PRA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, February 2nd. KeyCorp reissued a “buy” rating and issued a $100.00 price objective on shares of PRA Health Sciences in a research note on Wednesday, January 31st. Mizuho cut shares of PRA Health Sciences from a “buy” rating to a “neutral” rating and set a $86.00 price objective on the stock. in a research note on Wednesday, January 24th. Finally, Zacks Investment Research cut shares of PRA Health Sciences from a “buy” rating to a “hold” rating in a research note on Thursday, January 18th. Three analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $93.15.
PRA Health Sciences Profile
PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.